APA (7th ed.) Citation

Nahi, H., Usmani, S. Z., Mateos, M., van de Donk, N. W. C. J., Oriol, A., Plesner, T., . . . Moreau, P. (2023). Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: Part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & Lymphoma, 64(2), 468. https://doi.org/10.1080/10428194.2022.2148221

Chicago Style (17th ed.) Citation

Nahi, Hareth, et al. "Corticosteroid Tapering Is a Safe Approach in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-label, Multicenter, Phase 1b PAVO Study." Leukemia & Lymphoma 64, no. 2 (2023): 468. https://doi.org/10.1080/10428194.2022.2148221.

MLA (9th ed.) Citation

Nahi, Hareth, et al. "Corticosteroid Tapering Is a Safe Approach in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-label, Multicenter, Phase 1b PAVO Study." Leukemia & Lymphoma, vol. 64, no. 2, 2023, p. 468, https://doi.org/10.1080/10428194.2022.2148221.